无导线胫神经刺激器eCoin治疗急迫性尿失禁的关键性研究
这项前瞻性、开放标签、单臂关键性试验在美国15个中心纳入137例难治性急迫性尿失禁患者,植入无导线胫神经刺激器eCoin并自动刺激48周。结果显示68%(95%CI:60%-76%)的患者急迫性尿失禁发作较基线减少至少50%,16%的植入患者发生器械相关事件。
要点
- eCoin为无导线、电池供电的胫神经刺激器,微创植入小腿。
- 48周时68%患者急迫性尿失禁发作减少≥50%。
- 52周内16%植入患者出现器械相关事件。
核心结论
- eCoin自动间歇低占空比刺激对难治性急迫性尿失禁显示临床获益,且采用微创简短植入操作。
研究设计与样本
- 前瞻性、开放标签、单臂关键性试验,在美国15个医疗中心开展,纳入137例难治性急迫性尿失禁受试者。
- 137例中133例植入eCoin,132例纳入意向性治疗人群;该人群中98%为女性,平均年龄63.9±10.9岁,基线每日急迫性尿失禁发作4.3±3.1次。
主要发现
- 主要疗效分析显示,激活后48周时68%(95%CI:60%-76%)的受试者急迫性尿失禁发作较基线减少至少50%。
- 植入后至52周,16%的植入受试者发生器械相关事件。
关键数值与推荐
- 主要疗效指标为治疗48周后急迫性尿失禁发作较基线减少≥50%的受试者比例。
- 主要安全性指标为同一时间点的器械相关不良事件。
临床怎么用
- 对于难治性急迫性尿失禁患者,eCoin可作为一种微创植入的自动胫神经刺激选择。
局限性
- 本研究为开放标签、单臂设计,未设对照,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A novel leadless tibial nerve stimulator provides a primary battery-powered, coin-sized, minimally invasive option to deliver automatic low-duty cycle stimulation for overactive bladder syndrome therapy. A pivotal trial was conducted to evaluate the safety and efficacy of this investigational device, eCoin®, for treating refractory urgency urinary incontinence. MATERIALS AND METHODS: This was a prospective, open-label, single arm trial carried out at 15 U.S. medical centers involving 137 subjects with refractory urgency urinary incontinence. After implantation in the lower leg above the fascia over the tibial nerve, eCoin delivered automated stimulation sessions for the duration of the study. The primary efficacy measure was the proportion of subjects who achieved a 50% or greater reduction from baseline in urgency urinary incontinence episodes after 48 weeks of therapy. The primary safety measure was device-related adverse events at the same time point. RESULTS: Of 137 subjects enrolled, 133 were implanted with eCoin, and 132 were included in the intention-to-treat population. Of those 132 subjects, 98% were female, mean±SD age was 63.9±10.9 years, and baseline daily urgency urinary incontinence episodes were 4.3±3.1. The primary efficacy analysis showed 68% (95% CI: 60%-76%) of subjects experienced at least a 50% reduction in urgency urinary incontinence episodes at 48 weeks post-activation; 16% of implanted subjects experienced device-related events through 52 weeks post-implantation. CONCLUSIONS: eCoin demonstrated clinical benefit for treating overactive bladder syndrome with automatic delivery of an intermittent low-duty cycle and implanted with a minimally invasive, brief procedure.
引用
- Rogers A, Bragg S, Ferrante K, et al. Pivotal Study of Leadless Tibial Nerve Stimulation with eCoin® for Urgency Urinary Incontinence: An Open-Label, Single Arm Trial. J Urol. 2021. PMID: 33797291. doi:10.1097/JU.0000000000001733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。